Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer

Purpose: Mutations in the fibroblast growth factor receptor 3 (FGFR3) have been found in 70% of the low-grade non-muscle–invasive bladder cancer (NMI-BC) tumors. We aim to determine the potential of FGFR3 mutation analysis on voided urine to detect recurrences during surveillance of patients with low-grade NMI-BC. Experimental Design: FGFR3 mutation status of the study inclusion tumor was determined from 200 low-grade NMI-BC patients. Patients with an FGFR3-mutant inclusion tumor were selected for analysis and monitored by cystoscopy, and voided urine samples were collected. FGFR3 mutation analysis was done on 463 prospectively collected urines. Sensitivity and predictive value of the assay were determined for detection of concomitant recurrences. Longitudinal and Cox time-to-event analyses were done to determine the predictive value for detection of future recurrences. Results: Median follow-up was 3.5 years. The sensitivity of the assay for detection of concomitant recurrences was 26 of 45 (58%). Of the 105 positive urine samples, 85 (81%) were associated with a concomitant or a future recurrence. An FGFR3-positive urine was associated with a 3.8-fold (P < 0.0001) higher risk of having a recurrence in the Cox analysis. In contrast, only 41 of 358 (11%) FGFR3-negative urine samples were associated with a recurrence. Positive predictive value increased from 25% to 90% in patients having consecutive FGFR3-positive urine tests. Conclusions: FGFR3 mutation analysis on voided urine is a simple and noninvasive diagnostic method for detection of recurrences during surveillance of patients presenting with a low-grade FGFR3-mutant NMI-BC tumor. Clin Cancer Res; 16(11); 3011–8. ©2010 AACR.

[1]  Y. Kanai,et al.  Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non‐muscle invasive bladder cancer , 2010, Cancer Science.

[2]  A. Hartmann,et al.  No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer , 2009, International journal of cancer.

[3]  Y. Lotan,et al.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. , 2009, European urology.

[4]  T. H. van der Kwast,et al.  The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour , 2009, Journal of Pathology.

[5]  Ewout W Steyerberg,et al.  Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. , 2009, The Journal of urology.

[6]  F. Hamdy,et al.  FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. , 2009, European urology.

[7]  Ewout W Steyerberg,et al.  Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). , 2009, European urology.

[8]  T. H. van der Kwast,et al.  Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. , 2008, European urology.

[9]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[10]  Unyime Nseyo,et al.  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. , 2007, The Journal of urology.

[11]  K. Grigor,et al.  Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. , 2007, The Journal of urology.

[12]  F. Hamdy,et al.  [Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract]. , 2006, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[13]  N. Malats,et al.  Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Zwarthoff,et al.  A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine , 2005, Clinical Cancer Research.

[15]  T. Ratliff.  Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.

[16]  Dieter Jocham,et al.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. , 2005, The Journal of urology.

[17]  Antonio Alcaraz,et al.  Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. , 2005, The Journal of urology.

[18]  P. Mariappan,et al.  A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. , 2005, The Journal of urology.

[19]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[20]  K. Rieger-Christ,et al.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection , 2003, Cancer.

[21]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Holmäng,et al.  The Cost of Bladder Tumour Treatment and Follow-up , 2002, Scandinavian journal of urology and nephrology.

[23]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[24]  A. Formiconi,et al.  BTA Quantitative Assay and NMP22 Testing Compared with Urine Cytology in the Detection of Transitional Cell Carcinoma of the Bladder , 2000, Urologia Internationalis.

[25]  F. Millán-Rodríguez,et al.  Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. , 2000, The Journal of urology.

[26]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[27]  D J O'Kane,et al.  Comparison of screening methods in the detection of bladder cancer. , 1999, The Journal of urology.

[28]  W. Ellis,et al.  Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. , 1997, Urology.

[29]  L. Kiemeney,et al.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. , 1993, British Journal of Cancer.

[30]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  A. Orsola,et al.  Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14. , 2009, European urology.

[33]  E. Zwarthoff,et al.  Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.

[34]  Jörg Schmidbauer,et al.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. , 2004, The Journal of urology.

[35]  T. H. van der Kwast,et al.  Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Chopin,et al.  Short Communication Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors , 2001 .